Evolution of immunosuppression at the University of Minnesota

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S64-S70

  Matas, A J ^a   Sutherland, D E R ^a   Najarian, J S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ANESTHESIA; CADAVER KIDNEY; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIALYSIS; DRUG APPROVAL; DYSPNEA; FEVER; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LIVING DONOR; NEPHROTOXICITY; PATIENT CARE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; TREATMENT OUTCOME; UNITED STATES;

EID: 1642287622     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.062     Document Type: Article

References (46)

1. Najarian J.S., Simmons R.L., Gewurz H., et al. Anti-serum to cultured human lymphoblasts preparation, purification and immunosuppressive properties in man. Ann Surg. 170:1969;617.
2. Najarian J.S., Simmons R.L. The clinical use of antilymphocyte globulin. N Engl J Med. 285:1971;158.
3. Najarian J.S., Simmons R.L., Condie R.M., et al. Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg. 184:1976;352.
4. Simmons R.L., Uranga V.M., LaPlante E.S., et al. Pulmonary complications in transplant recipients. Arch Surg. 105:1972;260.
5. Simmons R.L., Lopez C., Balfour H. Jr, et al. Cytomegalovirus clinical virological correlations in renal transplant recipients. Ann Surg. 180:1974;623.
6. Lopez C., Simmons R.L., Mauer S.M., et al. Association of renal allograft rejection with virus infections. Am J Med. 56:1974;280.
7. Howard R.J., Kalis J.M., Balfour H.H. Jr, et al. Viral infections in kidney donors and recipients a prospective study. Transplant Proc. 9:1977;113.
8. Simmons R.L., Matas A.J., Rattazzi L.C., et al. Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation. Surgery. 82:1977;537.
9. Marker S.C., Howard R.J., Simmons R.L., et al. Cytomegalovirus infection a quantitative prospective study of three hundred twenty consecutive renal transplants. Surgery. 89:1981;660.
10. Peterson P.K., Balfour H.H. Jr, Marker S.C., et al. Cytomegalovirus disease in renal allograft recipients a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine (Baltimore). 59:1980;283.
11. Peterson P.K., Balfour H.H. Jr, Fryd D.S., et al. Fever in renal transplant recipients causes, prognostic significance and changing patterns at the University of Minnesota Hospital. Am J Med. 71:1981;345.
12. Balfour H.H. Jr, Chace B.A., Stapleton J.T., et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 320:1989;1381.
13. Dunn D.L., Gillingham K.J., Kramer M.A. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation. 57:1994;876.
14. Matas A.J., Simmons R.L., Buselmeier T.J., et al. Lethal complications of bilateral nephrectomy and splenectomy in hemodialyzed patients. Am J Surg. 129:1975;616.
15. Fryd D.S., Sutherland D.E., Simmons R.L., et al. Results of a prospective randomized study on the effect of splenectomy versus no splenectomy in renal transplant patients. Transplant Proc. 13:1981;48.
16. Sutherland D.E., Fryd D.S., So S.K., et al. Long-term effect of splenectomy versus no splenectomy in renal transplant patients. Reanalysis of a randomized prospective study. Transplantation. 38:1984;619.
17. Matas A.J., Sibley R., Mauer M., et al. The value of needle renal allograft biopsy. I. A retrospective study of biopsies performed during putative rejection episodes. Ann Surg. 197:1983;226.
18. Ferguson R.M., Rynasiewicz J.J., Sutherland D.E., et al. Cyclosporin A in renal transplantation a prospective randomized trial. Surgery. 92:1982;175.
19. Najarian J.S., Fryd D.S., Strand M., et al. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg. 201:1985;142.
20. Canafax D.M., Torres A., Fryd D.S., et al. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG-azathioprine. Transplantation. 41:1986;177.
21. Johnson C.P., Simmons R.L., Sutherland D.E., et al. A randomized trial comparing cyclosporine with antilymphoblast-globulin-azathioprine for renal allograft recipients. Results at 2 1/2-6 years. Transplantation. 45:1988;380.
22. Fryd D.S., Canafax D.M., Matas A.J., et al. A comparison of two cyclosporine protocols at the University of Minnesota. Terasaki P. Clinical Transplants 1988. 1988;p79 UCLA Tissue Typing Laboratory, Los Angeles, Calif.
23. Frey D.J., Matas A.J., Gillingham K.J., et al. Sequential therapy - a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation. 54:1992;50.
24. Wilson L.G. The crime of saving lives - The FDA, John Najarian, and Minnesota ALG. Arch Surg. 130:1995;1033.
25. Brennan D.C., Flavin K., Lowell J.A., et al. A randomized, double-blinded comparison of Thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 67:1999;1011.
26. Brennan D.C. Thymoglobulin Study Group Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: expanded results from a prospective randomized multicenter trial. Am J Transpl. 3:2003;438.
27. Myers B.D., Ross J., Newton L., et al. Cyclosporine-associated chronic nephropathy. N Engl J Med. 311:1984;699.
28. Moran M., Tomlanovich S., Myers B.D. Cyclosporine-induced chronic nephropathy in human recipients of cardiac allografts. Transplant Proc. 17:(4 suppl 1):1985;185.
29. Myers B.D., Sibley R., Newton L., et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 33:1988;590.
30. Schweitzer E.J., Matas A.J., Gillingham K.J., et al. Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s. Ann Surg. 214:1991;679.
31. Almond P.S., Matas A., Gillingham K., et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 55:1993;752.
32. Basadonna G.P., Matas A.J., Gillingham K.J., et al. Early versus late acute renal allograft rejection impact on chronic rejection. Transplantation. 55:1993;993.
33. 1/2). Transplantation. 57:1994;857.
34. Matas A.J., Humar A., Payne W.D., et al. Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann Surg. 230:1999;493.
35. Johnson E.M., Canafax D.M., Gillingham K.J., et al. Effect of early cyclosporine levels on kidney allograft rejection. Clin Transplant. 11:1997;552.
36. Matas A.J., Gillingham K.J., Chavers B.M., et al. The importance of early cyclosporine levels in pediatric kidney transplantation. Clin Transplant. 10:1996;482.
37. Almond P.S., Gillingham K.J., Sibley R., et al. Renal transplant function after ten years of cyclosporine. Transplantation. 53:1992;316.
38. Matas A.J., Almond P.S., Moss A. Effect of cyclosporine on renal function in kidney transplant recipients a 12-year follow-up. Clin Transplant. 9:1995;450.
39. Fryer J.P., Granger D.K., Leventhal J.R., et al. Steroid-related complications in the cyclosporine era. Clin Transplant. 8:1994;224.
40. Fryer J.P., Benedetti E., Gillingham K., et al. Steroid-related complications in pediatric kidney transplant recipients in the cyclosporine era. Transplant Proc. 26:1994;91.
41. Matas A.J., Payne W.D., Gillingham K.J., et al. Optimizing the immediate posttransplant prednisone dose - a prospective randomized trial. Clin Transplantation. 6:1992;73.
42. Ahsan N., Hricik D., Matas A., et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Steroid Withdrawal Study Group. Transplantation. 68:1999;1865.
43. Matas A.J., Ramcharan T., Paraskevas S., et al. Rapid discontinuation of steroids in living donor kidney transplantation a pilot study. Am J Transplant. 1:2001;278.
44. Khwaja K., Asolati M., Harmon J., et al. Successful rapid discontinuation of prednisone in high-risk kidney transplant recipients. Am J Transpl. 3:(suppl 5):2003;352.
45. Khwaja K., Asolati M., Harmon J., et al. 95% graft survival at 3 years posttransplant with steroid-free maintenance immunosuppression. Am J Transpl. 3:(suppl 5):2003;440.
46. Kandaswamy R., Humar A., Khwaja K., et al. A prospective randomized study of cyclosporine (CSA)/Cellcept (MMF) vs. tacrolimus (TAC)/sirolimus (SIR) with rapid discontinuation of prednisone (P). Am J Transpl. 3:(suppl 5):2003;198.